A patient presents with recurrent infections with Neisseria gonorrhoeae. Which of the following investigations is most appropriate to evaluate the underlying immunodeficiency?

Explanation

## Correct Answer: A. Terminal complement (C5–C9) assay Recurrent Neisseria gonorrhoeae infections are a classic presentation of **terminal complement deficiency (C5–C9 deficiency)**. The terminal complement complex (MAC: C5b-9) is essential for bactericidal killing of Gram-negative diplococci, particularly Neisseria species. Patients with deficiencies in C5, C6, C7, C8, or C9 cannot form the membrane attack complex and thus cannot lyse these organisms, leading to recurrent or disseminated gonococcal and meningococcal infections. This is a well-established immunological principle: while opsonization and phagocytosis may occur via earlier complement components, terminal complement is uniquely required for direct lysis of Neisseria. The clinical pearl is that recurrent gonococcal infection (especially if disseminated) should immediately raise suspicion for terminal complement deficiency. Assaying C5–C9 levels or functional complement activity (CH50 test followed by component-specific assays) is the gold standard investigation. In Indian clinical practice, this association is often tested because it represents a specific, actionable immunodeficiency that explains a narrow spectrum of infections (Neisseria species predominantly). ## Why the other options are wrong **B. C1 esterase inhibitor assay** — C1 esterase inhibitor deficiency causes hereditary angioedema (HAE), not recurrent infections. This is a regulatory protein defect affecting the contact system, not bactericidal immunity. While it affects complement, it does not predispose to Neisseria infections. This is an NBE trap pairing a complement protein with infection without understanding the functional role. **C. Quantitative immunoglobulin levels** — Hypogammaglobulinemia or selective Ig deficiency would cause recurrent infections with encapsulated organisms (S. pneumoniae, H. influenzae) and intracellular pathogens, not specifically Neisseria gonorrhoeae. Gonococcal infection is not the hallmark of antibody deficiency. This option tests whether students confuse antibody deficiency with complement deficiency. **D. Nitroblue tetrazolium test** — NBT test detects chronic granulomatous disease (CGD), a phagocytic oxidative burst defect. CGD patients suffer recurrent infections with catalase-positive organisms (S. aureus, Burkholderia, Serratia, Nocardia), not Neisseria. Neisseria is catalase-positive but does not characteristically cause recurrent infection in CGD. This is a distractor testing knowledge of phagocytic defects. ## High-Yield Facts - **Recurrent Neisseria gonorrhoeae infection** is pathognomonic for **terminal complement deficiency (C5–C9)** - **MAC (C5b-9)** is required for bactericidal lysis of Gram-negative diplococci; earlier complement components (C1–C4) cannot compensate - **CH50 test** (total hemolytic complement) is the screening test; if abnormal, component-specific assays (C5–C9) confirm deficiency - **Meningococcal disease** (recurrent or disseminated) is equally characteristic of terminal complement deficiency as gonococcal infection - **Early complement deficiency (C1–C4)** predisposes to autoimmune disease (SLE, GN); **terminal deficiency** predisposes to Neisseria infections ## Mnemonics **NEISSERIA = TERMINAL COMPLEMENT** Neisseria (gonorrhoeae & meningitidis) → Terminal complement (C5–C9) deficiency. Remember: Neisseria needs the MAC to die. No MAC = recurrent Neisseria. **MAC KILLS GRAM-NEGATIVE DIPLOCOCCI** Membrane Attack Complex (C5b-9) is the only complement pathway that directly lyses Gram-negative organisms. Phagocytosis alone is insufficient for Neisseria. ## NBE Trap NBE pairs complement deficiency with infection and offers multiple complement-related distractors (C1-INH, immunoglobulins, phagocytic defects). The trap is testing whether students know that **only terminal complement deficiency specifically predisposes to Neisseria**, not all complement or immune defects. ## Clinical Pearl In Indian clinical settings, a young adult presenting with recurrent gonococcal urethritis or disseminated gonococcal infection (DGI with arthritis/tenosynovitis) should prompt immediate complement screening. Terminal complement deficiency is rare but treatable (prophylactic antibiotics, vaccination against Neisseria); missing it leads to preventable morbidity. _Reference: Jawetz, Melnick & Adelberg's Medical Microbiology Ch. 22 (Neisseria); Harrison's Principles of Internal Medicine Ch. 372 (Complement Deficiencies)_